{"id":"NCT02159469","sponsor":"Antares Pharma Inc.","briefTitle":"Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism","officialTitle":"A Multiple-dose, 52-week Study to Evaluate the Efficacy and Safety of Testosterone Enanthate Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-07","primaryCompletion":"2015-02","completion":"2015-11","firstPosted":"2014-06-10","resultsPosted":"2018-01-09","lastUpdate":"2018-02-07"},"enrollment":150,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hypogonadism"],"interventions":[{"type":"COMBINATION_PRODUCT","name":"Testosterone enanthate auto-injector","otherNames":["Testosterone","Testosterone enanthate","QuickShotÂ® Testosterone (QST)"]}],"arms":[{"label":"Testosterone enanthate auto-injector","type":"EXPERIMENTAL"}],"summary":"Evaluation of efficacy and safety of testosterone enanthate administered subcutaneously using an auto-injector","primaryOutcome":{"measure":"Percentage of Patients With Total Testosterone Cavg(0-168h) Serum Concentrations Within the Normal Range (300-1100 ng/dL)","timeFrame":"12 weeks","effectByArm":[{"arm":"Testosterone Enanthate Auto-injector","deltaMin":139,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":23},"locations":{"siteCount":28,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":150},"commonTop":["Hematocrit increased","Hypertension","Prostatic specific antigen increased","Upper respiratory tract infection","Sinusitis"]}}